Navigation Links
Abbott and Oasmia Pharmaceutical Announce Exclusive Distribution Agreement for Paccal(R) Vet, a New Chemotherapeutic Agent for Dogs
Date:7/10/2009

ABBOTT PARK, Ill. and UPPSALA, Sweden, July 10 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) and Oasmia Pharmaceutical have announced a multi-year agreement to market one of the first cancer medications for dogs. The chemotherapeutic agent, called Paccal(R) Vet (micellar paclitaxel), represents the first generation of treatments of its kind and is currently being studied to treat Grade II and Grade III canine mast cell tumors where curative surgery cannot be performed.

Under the terms of the agreement, Abbott will obtain exclusive rights to distribute Paccal Vet for veterinary use in the United States and Canada, and will be responsible for sales and marketing. Oasmia is responsible for clinical development, manufacturing and registration. Financial terms were not disclosed.

Paccal Vet is a new formulation of the active ingredient paclitaxel. Paclitaxel has been used in treating cancer in humans since 1993. Traditional formulations of paclitaxel were insoluble in water, thus requiring the medication to be dissolved in solvents, which led to low tolerability and severe adverse effects in dogs. Paccal Vet uses a novel, non-toxic nanoparticle formulation that overcomes those challenges and provides a high level of water solubility. If approved, Paccal Vet would be one of the first cancer treatments specifically designed for veterinary use.

The move into veterinary oncology adds a new focus area to Abbott's existing Animal Health research and product lines, which include diabetes, anesthesia, wound care, pain management and fluid therapy.

"There are significant unmet needs in this market, which is why Abbott is entering the veterinary oncology arena," said Lynn Bromstedt, divisional vice president and general manager, Abbott Animal Health. "Paccal Vet would be one the first medications of its k
'/>"/>

SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Abbott Hosts Conference Call for Second-Quarter Earnings
2. Abbott Receives CE Mark for Companys Next-Generation XIENCE PRIME(TM) Drug Eluting Stent, Advancing Leadership Position
3. Schmidt & Clark, LLP: FDA Reports Show Abbott Labs Subsidiary Failed to Disclose Parasite Eye Infections Tied to Contact Lens Solution
4. Abbott Initiates Trial of Next-Generation XIENCE PRIME(TM) Drug Eluting Stent, Building Upon Superior Outcomes from SPIRIT Family of Trials
5. Abbott Declares 342nd Consecutive Quarterly Dividend
6. Abbott Announces Launch of Next-Generation Embolic Protection System
7. Abbott Announces New EAS(R) Myoplex(R) Strength Formula Nutrition Shake and Debuts Bottle Packaging
8. Abbotts TRILIPIX(R) (Fenofibric Acid) in Combination With Rosuvastatin Calcium Helps Patients With Mixed Dyslipidemia and Type 2 Diabetes Meet American Diabetes Association Lipid Targets
9. Abbott and AstraZeneca Extend Relationship to Include Co-Promotion of TRILIPIX(R) (fenofibric acid)
10. Abbott and AstraZeneca Submit New Drug Application to the FDA for CERTRIAD(TM), an Investigational Treatment for Mixed Dyslipidemia
11. Abbott to Present at Goldman Sachs Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... 2014 The first ORTC Public ... Microsoft, and Google. ( http://ortc.org/wp-content/uploads/2014/08/ortc.html ) , ... to create a WebRTC 1.1 API with exceptional ... WebRTC, ORTC (Object Real-time Communication) enables plugin-free real-time ... specifically tailored to provide the direct control needed ...
(Date:8/22/2014)... 22, 2014 The Berkowitz Law Firm ... a client who suffered severe, permanent injuries in an ... driver (docket number FST-CV13-6018309-S). The case was pending in ... According to Jennifer Amdur of The Berkowitz Law Firm ... all of whom were allegedly injured following ...
(Date:8/22/2014)... FastFingerprints is adding a new location to ... Wednesday, August 27, 2014 and is located at 3740 ... the addition of this new office, that will bring ... Cleveland area. Our new Cleveland-Midtown location will provide ... hours of operation will be Monday-Friday 8:00am – 5:00pm ...
(Date:8/22/2014)... 22, 2014 Teen substance abuse has ... OH. Unfortunately, most young adults never receive the professional ... the community, the new Troubled Teens Columbus helpline was ... to overcome their drug and alcohol dependencies . ... teens and their parents can speak directly to a ...
(Date:8/22/2014)... 2014 Dr Murray Grossan was interviewed for ... , In the October 2014 issue of Bottom Line Personal ... his method of treating snoring, and in some cases Obstructive ... half of all adults snore occasionally, and about 25% do ... air passages in the back of the throat tend to ...
Breaking Medicine News(10 mins):Health News:Hookflash, Google and Microsoft lead on ORTC / WebRTC 1.1 Public Draft 2Health News:Hookflash, Google and Microsoft lead on ORTC / WebRTC 1.1 Public Draft 3Health News:The Berkowitz Law Firm LLC Reaches a $2 Million Settlement for a Client Allegedly Injured in Drunk Driving Accident 2Health News:FastFingerprints Expands In The Cleveland Ohio Area 2Health News:FastFingerprints Expands In The Cleveland Ohio Area 3Health News:New Helpline in Columbus Assists Troubled Teen Find Youth Rehab 2Health News:Dr Murray Grossan Explains how and why Singing Exercises Stop Snoring 2Health News:Dr Murray Grossan Explains how and why Singing Exercises Stop Snoring 3
... VNDA ) ("Vanda" or the "Company") announced today ... contest by withdrawing its nominations of director candidates for election ... liquidate the Company. TCP had previously notified the Company of ... of its candidates to the Vanda Board at the Company,s ...
... is National Lupus Awareness MonthWASHINGTON, May 7 ... risks associated with breast cancer and heart disease, but ... aware of another potentially fatal disease that disproportionately strikes ... The disease is lupus.Although more than 1.5 million ...
... May 7 /PRNewswire-Asia-FirstCall/ -- China Pharma,Holdings, Inc. ("China Pharma") ... pharmaceutical products in China, today,announced that it plans to ... 2009, before the market opens. , ... 8:00 am ET on May 15, 2009 to,discuss fiscal ...
... (NYSE: MTD ) today announced the webcast of its ... Conference in New York on Thursday, May 14, 2009, at 10:40 ... presentation, visit the investor relations page on the Company,s Web site ... /investors . A replay of the webcast will be ...
... Recent scientific studies published in the medical journals ... Journal of Nutrition, and others, showed that the ... anti-cancer activities. Gene-Eden is a dietary supplement ... unique, patent-pending formulation. Gene-Eden was introduced in February ...
... Systems Inc. (OTC Bulletin Board: PLCSF), a company focused on ... results for the three month period ended March 31, 2009. ... in the first quarter of 2008. The net loss for ... diluted share, compared to a net loss of $762,000, or ...
Cached Medicine News:Health News:Vanda Pharmaceuticals Announces Withdrawal of Director Nominees and Proposal to Liquidate Submitted by Tang Capital 2Health News:Public Lacks Awareness of Serious Disease With Life-Threatening Complications 2Health News:Public Lacks Awareness of Serious Disease With Life-Threatening Complications 3Health News:China Pharma Holdings, Inc. to Report First Quarter 2009 Financial Results on May 15, 2009 2Health News:The Center for the Biology of Chronic Disease Highlights Anti-Cancer Activities of the Food Extracts Quercetin, EGCG, Glycyrrhizin, and Trans-Cinnamaldehyde 2Health News:PLC Systems Reports First Quarter 2009 Results 2Health News:PLC Systems Reports First Quarter 2009 Results 3Health News:PLC Systems Reports First Quarter 2009 Results 4Health News:PLC Systems Reports First Quarter 2009 Results 5
(Date:8/21/2014)... Aug. 21, 2014 Asterias Biotherapeutics, Inc. (OTCBB: ... of regenerative medicine, announced today the appointments of Andrew ... newly expanded Board of Directors. With these additions, the ... of whom are independent. Andy Arno ... emerging growth companies. He is currently Managing Director of ...
(Date:8/20/2014)... Aug. 20, 2014  The National Association of ... results achieved by the real-time, pseudoephedrine (PSE) blocking ... Precursor Log Exchange (NPLEx), automatically blocks unlawful PSE ... meth offenders and make arrests. Data released by ... blocked the sale of more than ...
(Date:8/20/2014)... 20, 2014  The National Association of Drug ... achieved by the real-time, pseudoephedrine (PSE) blocking system ... Log Exchange (NPLEx), automatically blocks unlawful pseudoephedrine sales ... offenders and make arrests. Data released by NPLEx ... blocked the sale of more than 19,030 ...
Breaking Medicine Technology:Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 2Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 3Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 4Indiana's Stop-Sale System Achieves Significant Results In Battle Against Meth 2Missouri's Stop-Sale System Achieves Significant Results In Battle Against Meth 2
Standard Deflectable Catheters...
The Explorer ST "soft tip" catheter has a proximal shaft with a soft tip. It is available in both a 5F and 6F shaft configuration....
... offers a wide range of deflectable curve ... needs of children and other patients with ... demanding specifications using only the finest materials. ... wire braiding and extrusion technologies results in ...
A-Focus I & II Catheters. A-Focus steerable atrial mapping catheter. Available in 10, 12, 14 and 20 electrode configurations. (Shown with 14 electrodes)....
Medicine Products: